How to buy Cerus Corporation stock

Cerus Corporation is a biotechnology business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Cerus Corporation employs 254 staff and has a trailing 12-month revenue of around 0.00.

Cerus Corporation share price

Use our graph to track the performance of CERS stocks over time.

Cerus Corporation shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$5.05 - $8.87
50-day moving average	$6.09
200-day moving average	$6.61
Wall St. target price	$9.10
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.49

Buy Cerus Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cerus Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cerus Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cerus Corporation financials

Revenue TTM	$84.6 million
Gross profit TTM	$41.2 million
Return on assets TTM	-19.98%
Return on equity TTM	-73.39%
Profit margin	-73.73%
Book value	$0.65
Market capitalisation	$1 billion

TTM: trailing 12 months

Shorting Cerus Corporation shares

There are currently 12.8 million Cerus Corporation shares held short by investors – that's known as Cerus Corporation's "short interest". This figure is 13.4% down from 14.8 million last month.

There are a few different ways that this level of interest in shorting Cerus Corporation shares can be evaluated.

Cerus Corporation's "short interest ratio" (SIR)

Cerus Corporation's "short interest ratio" (SIR) is the quantity of Cerus Corporation shares currently shorted divided by the average quantity of Cerus Corporation shares traded daily (recently around 2.4 million). Cerus Corporation's SIR currently stands at 5.23. In other words for every 100,000 Cerus Corporation shares traded daily on the market, roughly 5230 shares are currently held short.

However Cerus Corporation's short interest can also be evaluated against the total number of Cerus Corporation shares, or, against the total number of tradable Cerus Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerus Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cerus Corporation shares in existence, roughly 50 shares are currently held short) or 0.0556% of the tradable shares (for every 100,000 tradable Cerus Corporation shares, roughly 56 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cerus Corporation.

Find out more about how you can short Cerus Corporation stock.

Cerus Corporation share dividends

We're not expecting Cerus Corporation to pay a dividend over the next 12 months.

Cerus Corporation share price volatility

Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $5.05 up to $8.87. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.334. This would suggest that Cerus Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cerus Corporation overview

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California. .

Frequently asked questions

• What percentage of Cerus Corporation is owned by insiders or institutions?

  Currently 2.081% of Cerus Corporation shares are held by insiders and 78.569% by institutions.

• How many people work for Cerus Corporation?

  Latest data suggests 254 work at Cerus Corporation.

• When does the fiscal year end for Cerus Corporation?

  Cerus Corporation's fiscal year ends in December.

• Where is Cerus Corporation based?

  Cerus Corporation's address is: 1220 Concord Avenue, Concord, CA, United States, 94520

• What is Cerus Corporation's ISIN number?

  Cerus Corporation's international securities identification number is: US1570851014

• What is Cerus Corporation's CUSIP number?

  Cerus Corporation's Committee on Uniform Securities Identification Procedures number is: 157085101